Xylia Q. Peters

Durban, ZN, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Potential of nanocarrier-mediated delivery of vancomycin for MRSA infections.

Potential of nanocarrier-mediated delivery of vancomycin for MRSA infections.

Journal: Expert opinion on drug delivery

Published: February 14, 2025

Multifunctional Dual Enzyme-Responsive Nanostructured Lipid Carriers for Targeting and Enhancing the Treatment of Bacterial Infections.

Multifunctional Dual Enzyme-Responsive Nanostructured Lipid Carriers for Targeting and Enhancing the Treatment of Bacterial Infections.

Journal: ACS applied bio materials

Published: December 23, 2024

Antimicrobial peptide-fucoidan nanoplexes: A novel multifunctional biomimetic nanocarrier for enhanced vancomycin delivery against bacterial infections and sepsis.

Antimicrobial peptide-fucoidan nanoplexes: A novel multifunctional biomimetic nanocarrier for enhanced vancomycin delivery against bacterial infections and sepsis.

Journal: International journal of pharmaceutics

Published: December 09, 2024

Engineering dynamic covalent bond-based nanosystems for delivery of antimicrobials against bacterial infections.

Engineering dynamic covalent bond-based nanosystems for delivery of antimicrobials against bacterial infections.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: January 27, 2024

Therapeutic Path to Triple Knockout: Investigating the Pan-inhibitory Mechanisms of AKT, CDK9, and TNKS2 by a Novel 2-phenylquinazolinone Derivative in Cancer Therapy- An In-silico Investigation Therapy.

Therapeutic Path to Triple Knockout: Investigating the Pan-inhibitory Mechanisms of AKT, CDK9, and TNKS2 by a Novel 2-phenylquinazolinone Derivative in Cancer Therapy- An In-silico Investigation Therapy.

Journal: Current pharmaceutical biotechnology

Published: February 27, 2023

Pharmacophore-based Identification of Potential Mutant Isocitrate Dehydrogenases I/2 Inhibitors: An Explorative Avenue in Cancer Drug Design.

Pharmacophore-based Identification of Potential Mutant Isocitrate Dehydrogenases I/2 Inhibitors: An Explorative Avenue in Cancer Drug Design.

Journal: Anti-cancer agents in medicinal chemistry

Published: July 04, 2022

Exploring the Effects of Chirality of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2- yl)phenyl]imidazolidine-2,4-dione and its Derivatives on the Oncological Target Tankyrase 2. Atomistic Insights.

Exploring the Effects of Chirality of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2- yl)phenyl]imidazolidine-2,4-dione and its Derivatives on the Oncological Target Tankyrase 2. Atomistic Insights.

Journal: Current pharmaceutical biotechnology

Published: June 08, 2022

Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy.

Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy.

Journal: Cell biochemistry and biophysics

Published: March 16, 2022

Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.

Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.

Journal: Anti-cancer agents in medicinal chemistry

Published: April 19, 2019

Showing 1-9 of 9

Last Updated: 09/26/2026